President Trump’s August 18, 2026, nomination of White House domestic policy deputy Heidi Overton to lead the FDA has set up a Senate confirmation process that will determine the outcome. Overton, a physician with prior service in the first Trump administration and the America First Policy Institute, has coordinated health policy including MAHA initiatives alongside HHS Secretary Robert F. Kennedy Jr. The agency remains unsettled after former commissioner Marty Makary’s May resignation, with ongoing staff reductions and morale concerns. Senate HELP Committee chair Bill Cassidy has publicly raised concerns over Overton’s involvement in a recent childhood vaccine executive order and her managerial experience, signaling potential opposition that could affect committee advancement or a floor vote. Confirmation requires navigating these Senate dynamics in the coming weeks.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$14,094 KL.
Sep 30, 2026
September 30
21%
October 31
35%
November 30
36%
December 31
40%
$14,094 KL.
September 30
$7,146 KL.
21%
October 31
$3,427 KL.
35%
November 30
$1,029 KL.
36%
December 31
$2,492 KL.
40%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump’s August 18, 2026, nomination of White House domestic policy deputy Heidi Overton to lead the FDA has set up a Senate confirmation process that will determine the outcome. Overton, a physician with prior service in the first Trump administration and the America First Policy Institute, has coordinated health policy including MAHA initiatives alongside HHS Secretary Robert F. Kennedy Jr. The agency remains unsettled after former commissioner Marty Makary’s May resignation, with ongoing staff reductions and morale concerns. Senate HELP Committee chair Bill Cassidy has publicly raised concerns over Overton’s involvement in a recent childhood vaccine executive order and her managerial experience, signaling potential opposition that could affect committee advancement or a floor vote. Confirmation requires navigating these Senate dynamics in the coming weeks.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Thị trường mở: Aug 20, 2026, 5:43 PM ET
Khối lượng
$14,094Ngày kết thúc
Jan 1, 2027Thị trường mở
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump’s August 18, 2026, nomination of White House domestic policy deputy Heidi Overton to lead the FDA has set up a Senate confirmation process that will determine the outcome. Overton, a physician with prior service in the first Trump administration and the America First Policy Institute, has coordinated health policy including MAHA initiatives alongside HHS Secretary Robert F. Kennedy Jr. The agency remains unsettled after former commissioner Marty Makary’s May resignation, with ongoing staff reductions and morale concerns. Senate HELP Committee chair Bill Cassidy has publicly raised concerns over Overton’s involvement in a recent childhood vaccine executive order and her managerial experience, signaling potential opposition that could affect committee advancement or a floor vote. Confirmation requires navigating these Senate dynamics in the coming weeks.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Khối lượng
$14,094Ngày kết thúc
Jan 1, 2027Thị trường mở
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump’s August 18, 2026, nomination of White House domestic policy deputy Heidi Overton to lead the FDA has set up a Senate confirmation process that will determine the outcome. Overton, a physician with prior service in the first Trump administration and the America First Policy Institute, has coordinated health policy including MAHA initiatives alongside HHS Secretary Robert F. Kennedy Jr. The agency remains unsettled after former commissioner Marty Makary’s May resignation, with ongoing staff reductions and morale concerns. Senate HELP Committee chair Bill Cassidy has publicly raised concerns over Overton’s involvement in a recent childhood vaccine executive order and her managerial experience, signaling potential opposition that could affect committee advancement or a floor vote. Confirmation requires navigating these Senate dynamics in the coming weeks.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp